|
GB201003949D0
|
|
Inhibitors of protein kinases
|
|
WO2008065155A1
|
|
Cdk inhibitors for treating pain
|
|
GB0719877D0
|
|
Inhibitors of protein kinases
|
|
WO2006125616A2
|
|
Pyrimidine-based cdk inhibitors for treating pain
|
|
WO2006070012A1
|
|
Agents useful in treating inflammatory bowel disease
|
|
EP1827479A1
|
|
Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
|
|
WO2006061418A2
|
|
Methods and agents useful in treating conditions characterized by mucus hyperproduction/hypersecretion
|
|
EP1786262A1
|
|
Methods for the production of improved live stocks and disease models for therapeutic research
|
|
WO2006018316A1
|
|
Methods for the production of improved live stocks and disease models for therapeutic research
|
|
WO2006002902A2
|
|
Methods for the production of improved live stocks and disease models for therapeutic research
|
|
WO2005107447A2
|
|
Methods for the production of improved live stocks and disease models for therapeutic research
|
|
EP1613649A2
|
|
Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
|
|
AU2003296724A8
|
|
Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
|
|
AU2003296554A1
|
|
Animal with modification of cytoplasmic dynein heavy chain 1 gene
|
|
AU2003264140A1
|
|
Modified phospholipase c-gamma-2, expression products, and non-human animal models comprising said genes, and therapeutic uses
|
|
AU2003242633A1
|
|
Dudulin genes, non-human animal model: uses in human hematological disease
|
|
WO03025580A1
|
|
Parallel miniaturized quantitative immunoassays
|
|
WO03004528A1
|
|
Human g protein-coupled receptors and uses thereof
|
|
EP1321515A1
|
|
Method of culturing cells
|
|
WO0200001A2
|
|
HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR20, AND USES THEREOF
|
